Lilly Gets First Of Its Kind FDA Citation For Trulicity Instagram Post

Promotion does not adequately communicate the diabetes drug’s indication, limits of use and risks, FDA says. It objects to distracting visuals in video and less prominent risk information. Agency had previously relayed its concerns to Lilly about Trulicity promotions.

A week after Eli Lilly and Company appeased the US Food and Drug Administration’s concerns about television advertisements for Emgality, it was rebuked for an Instagram post promoting its diabetes drug Trulicity.

The agency sent a 19 January untitled letter to Lilly objecting to the social media post, “Trulicity 2020 Instagram Ad – 10,080 Minutes

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Lilly Gets First Of Its Kind FDA Citation For Trulicity Instagram Post

Read the full article – start your free trial today!

More from Marketing & Advertising

More from Compliance